Market Place
Sourcing Support
4DMT Announces Presentation At 2024 Cystic Fibrosis Meeting
23 Sep 2024 //
GLOBENEWSWIRE
4DMT Highlights 4D-150 Data At AMD Development Day
18 Sep 2024 //
GLOBENEWSWIRE
4DMT to Participate in the 2024 Cantor Global Healthcare Conference
03 Sep 2024 //
GLOBENEWSWIRE
4DMT To Participate In H.C. Wainwright Ophthalmology Conference
12 Aug 2024 //
GLOBENEWSWIRE
4DMT Reports Second Quarter 2024 Financial Results and Operational Highlights
08 Aug 2024 //
GLOBENEWSWIRE
4DMT Advances Ophthalmology Leadership With New Hires And Advisory Board
05 Aug 2024 //
GLOBENEWSWIRE
Investors sour on 4DMT`s wet AMD gene therapy results, stock tumbles
18 Jul 2024 //
PRESS RELEASE
4DMT Reports Positive Phase 2 Data For 4D-150 In Wet AMD
17 Jul 2024 //
GLOBENEWSWIRE
4DMT Presents 24-Week Analysis From 4D-150 Phase 2 PRISM Cohort In Wet AMD
18 Jun 2024 //
GLOBENEWSWIRE
4DMT Presents Injection-Free Subgroup Analyses from 4D-150 Phase 2 at Summit
07 Jun 2024 //
GLOBENEWSWIRE
4DMT Presents Positive Data From Ph 1/2 AEROW Trial Of Aerosolized 4D-710
06 Jun 2024 //
GLOBENEWSWIRE
4DMT Announces Presentations at Clinical Trials at the Summit 2024 Meeting
04 Jun 2024 //
GLOBENEWSWIRE
4DMT to Participate in Upcoming Investor Conferences
03 Jun 2024 //
GLOBENEWSWIRE
4DMT To Present Inhaled 4D-710 Data In Cystic Fibrosis At ECFC
30 May 2024 //
GLOBENEWSWIRE
4DMT Reports First Quarter 2024 Financial Results and Operational Highlights
09 May 2024 //
GLOBENEWSWIRE
4DMT to Participate in Upcoming Investor Conference
07 May 2024 //
GLOBENEWSWIRE
4DMT Announces Presentations at ARVO 2024 Annual Meeting
01 May 2024 //
GLOBENEWSWIRE
4DMT Announces Update on Reg & Develop Path for 4D-710 for Cystic Fibrosis
28 Mar 2024 //
GLOBENEWSWIRE
4DMT to Participate in Upcoming Investor Conferences
04 Mar 2024 //
GLOBENEWSWIRE
4DMT Reports Full Year 2023 Financial Results and Operational Highlights
29 Feb 2024 //
GLOBENEWSWIRE
4DMT Presents Interim Data from 4D-310 INGLAXA Phase 1/2 Clinical Trials
12 Feb 2024 //
GLOBENEWSWIRE
4D Molecular Announces Pricing of Upsized Public Offering of Common Stock
06 Feb 2024 //
GLOBENEWSWIRE
4D Molecular Therapeutics Announces Proposed Public Offering of Common Stock
05 Feb 2024 //
GLOBENEWSWIRE
4DMT Presents Positive Data from Phase 2 Trial of Intravitreal 4D-150
03 Feb 2024 //
GLOBENEWSWIRE
4DMT to Host Webcast to Discuss Interim Data from Phase 2 of Intravitreal 4D-150
29 Jan 2024 //
GLOBENEWSWIRE
4DMT Receives Rare Pediatric Disease Designation from FDA for Aerosolized
23 Jan 2024 //
GLOBENEWSWIRE
4DMT Highlights Recent Clinical Pipeline Progress
04 Jan 2024 //
GLOBENEWSWIRE
4DMT Receives FDA RMAT Designation for 4D-150
21 Dec 2023 //
GLOBENEWSWIRE
4DMT to Present 24 Week Data from Randomized Phase 2 PRISM Trial of 4D-150
04 Dec 2023 //
GLOBENEWSWIRE
4DMT to Participate in Upcoming Investor Conferences
15 Nov 2023 //
GLOBENEWSWIRE
4DMT Reports Third Quarter 2023 Financial Results and Operational Highlights
09 Nov 2023 //
GLOBENEWSWIRE
4DMT Presents Positive Interim Data from Phase 1/2 AEROW Trial of Aerosolized
01 Nov 2023 //
GLOBENEWSWIRE
4DMT gets closer to lifting FDA hold on Fabry disease program
30 Oct 2023 //
FIERCE BIOTECH
4DMT to Present Data fromPhase 1/2 Trial for Cystic Fibrosis at 2023 NACFC
25 Oct 2023 //
GLOBENEWSWIRE
4DMT Receives EMA PRIME Designation for 4D-150 Genetic Medicine
23 Oct 2023 //
GLOBENEWSWIRE
4DMT Appoints Uneek Mehra as Chief Financial and Business Officer
12 Sep 2023 //
GLOBENEWSWIRE
4DMT Announces First Patient Enrolled in 4D-150 Phase 2 Trial in DME
07 Sep 2023 //
GLOBENEWSWIRE
4DMT to Participate in Upcoming Investor Conferences
07 Sep 2023 //
GLOBENEWSWIRE
4D Molecular Therapeutics Reports Second Quarter 2023 Financial Results
09 Aug 2023 //
GLOBENEWSWIRE
4DMT Presents Positive Interim Data from Intravitreal 4D-150 Ph 1/2 PRISM Trial
29 Jul 2023 //
PRESS RELEASE
4DMT Completes Enrollment of Phase 2 PRISM Trial for Intravitreal 4D-150
17 Jul 2023 //
GLOBENEWSWIRE
Astellas to test out 4DMT`s eye disease gene therapy vector
11 Jul 2023 //
FIERCE BIOTECH
4DMT Presents Positive Data from Aerosolized 4D-710 Phase 1/2 AEROW Trial
07 Jun 2023 //
GLOBENEWSWIRE
4D Molecular Therapeutics to Participate in Upcoming Investor Conferences
01 Jun 2023 //
GLOBENEWSWIRE
4DMT to Present Interim Data from 4D-710 Phase 1/2 AEROW Clinical Trial
24 May 2023 //
GLOBENEWSWIRE
4DMT Announces Presentation on Aerosolized 4D-710 for Cystic Fibrosis
11 May 2023 //
GLOBENEWSWIRE
4D Molecular Therapeutics Reports 1Q 2023FYR &Operational Highlights
10 May 2023 //
GLOBENEWSWIRE
4D Molecular Therapeutics Announces Closing of Upsized Public Offering
09 May 2023 //
GLOBENEWSWIRE
4D Molecular Therapeutics to Participate in Upcoming Investor Conferences
08 May 2023 //
GLOBENEWSWIRE
4D Molecular Therapeutics Announces Proposed Public Offering of Common Stock
04 May 2023 //
GLOBENEWSWIRE
4D Molecular Therapeutics Announces Pricing of Upsized PO of Common Stock
04 May 2023 //
GLOBENEWSWIRE
4DMT Presents Positive Interim Data from Intravitreal 4D-150 Phase 1/2 PRISM
27 Apr 2023 //
GLOBENEWSWIRE
4DMT Acquires Pathway Inhibitor Payload for 4D-175 Product Candidate
24 Apr 2023 //
GLOBENEWSWIRE
4DMT to Present Data from 4D-150 Phase 1/2 PRISM Trial for Wet AMD at ARVO
13 Apr 2023 //
PRESS RELEASE
4DMT to Present Data from 4D-150 Phase 1/2 PRISM Clinical Trial for Wet AMD
13 Apr 2023 //
GLOBENEWSWIRE
4D Molecular Reports Full Year 2022 Financial Results
15 Mar 2023 //
GLOBENEWSWIRE
4D Molecular Presents Data from 4D-310 INGLAXA Phase 1/2 Clinical Trials
22 Feb 2023 //
GLOBENEWSWIRE
4DMT to Present Interim Clinical Data from INGLAXA Phase 1/2 Trials of 4D-310
16 Feb 2023 //
GLOBENEWSWIRE
4D Molecular to Participate in the SVB Securities Global Biopharma Conference
08 Feb 2023 //
GLOBENEWSWIRE
4D in unknown dimension as FDA slaps hold on Fabry gene therapy trial
04 Feb 2023 //
FIERCE BIOTECH
